Comparative Pharmacology
Head-to-head clinical analysis: LEVONEST versus ZOVIA 1 35E 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVONEST versus ZOVIA 1 35E 28.
LEVONEST vs ZOVIA 1/35E-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a synthetic progestin that inhibits ovulation by suppressing luteinizing hormone (LH) surge, alters cervical mucus to impede sperm penetration, and induces endometrial changes that inhibit implantation.
ZOVIA 1/35E-28 is a combined oral contraceptive (COC) containing ethinyl estradiol and norethindrone. It inhibits ovulation via suppression of gonadotropins (FSH and LH), increases cervical mucus viscosity, and alters endometrial receptivity.
One tablet (levonorgestrel 1.5 mg) orally as a single dose within 72 hours of unprotected intercourse.
One tablet orally once daily at the same time each day for 21 days, followed by 7 days of placebo (inactive tablets), then repeat.
None Documented
None Documented
The terminal elimination half-life is approximately 24-30 hours. This relatively long half-life supports once-daily dosing and allows for stable plasma concentrations within 5-7 days of continuous use.
Ethinyl estradiol: ~17 hours (range 13-27 hours); Norethindrone: ~8 hours (range 5-14 hours). Clinical context: Steady state achieved in ~5-7 days; contraceptive effect requires consistent dosing.
Renal excretion of conjugated metabolites accounts for approximately 60-80% of an administered dose; fecal elimination via bile accounts for 20-40%.
Renal: ~40% as metabolites; biliary/fecal: ~40% as metabolites; unchanged drug minimal (<1%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive